ReviewDermatologie (Heidelberg, Germany)2025
[Systemic treatment of allergies].
Review in Dermatologie (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinokonjunctivitis or asthma bronchiale and urticaria with or without angioedema are the most prevalent allergic diseases in childhood. Symptomatic relief can be achieved with antihistamines, corticosteroids and partially with the anti-immunoglobulin E (IgE) antibody omalizumab. Bradykinin-dependent angioedema, especially in childhood as the primary manifestation of hereditary angioedema (HAE), has to be ruled out as a differential diagnosis of histamine-induced angioedema. For HAE different therapy options in acute attacks and long-term prophylaxis are available. Timely initiation of specific immunotherapy for IgE-mediated allergy to aeroallergens, sublingually or subcutaneously (SCIT) applied, should be considered. Insect venom allergy can be treated with SCIT. Diagnosis of eosinophilic esophagitis is often delayed. Bolus events may be indicative of the disease. Elimination diets, proton pump inhibitors, topical corticosteroids and dupilumab may be used.
Indexed as
Identifiers
40097816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.